Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Closure of trading window
Regulatory Filings Classification · 95% confidence The document text is extremely short (399 characters) and contains only address and stock exchange listing information without any substantive content, financial data, or report details. There is no indication of a full report, announcement of voting results, management changes, or any other specific filing content. It appears to be a minimal regulatory or listing-related notice without detailed information. Given the lack of content and the nature of the text, the best classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous or minimal regulatory announcements.
2022-03-31 English
This is to inform you that pursuant to the NSE circular no. NSE/CML/2019/11 and BSE circular no. LIST/COMP/01/2019-20 read with clause 4 of Schedule B of the SEBI (Prohibition of SEBI Insider ....
Regulatory Filings
2022-03-31 English
Post Offer Public announcement
Regulatory Filings
2022-02-25 English
Arihant Capital Markets Ltd ("Manager to the Offer") has submitted to BSE a copy of Post Offer Advertisement to the Shareholders of Lyka Labs Ltd ("Target Company").
Regulatory Filings
2022-02-25 English
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, which pertains to stop transfer of shares. The content includes details about stop transfer dates, folio numbers, shareholder names, certificate numbers, distinctive numbers, number of shares, and reasons for stop transfer (e.g., lost by holder). This is a regulatory compliance disclosure related to share transfer restrictions rather than a financial report, management change, or meeting material. The document is short (1492 characters) and primarily provides regulatory information about share transfer status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-24 English
Loss of share certificate
Regulatory Filings
2022-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.